Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Esophagus
Published in: Esophagus 1/2016

01-01-2016 | Original Article

Association of interleukin-1B gene polymorphisms at site 511 with gastroesophageal reflux disease: a meta-analysis

Authors: Minmin Xue, Sujuan Zhang, Jia Li, Wei Li, Dongxu Wang

Published in: Esophagus | Issue 1/2016

Login to get access

Abstract

Objectives

Multiple factors including genetic and environmental factors play a role in the pathogenesis of gastroesophageal reflux disease (GERD). The objective of this study was to quantitatively evaluate the association between Interleukin-1B-511 gene polymorphism and GERD susceptibility.

Methodology

Medline, CBM, VIP, CNKI, and Wanfang database were searched up to July 2014. Two reviewers independently assessed abstract of those searched articles. Finally, eight studies fulfilled our inclusion and exclusion criterion. Data about IL-1B-511 gene polymorphism and GERD condition were extracted and combined using the random-effect model.

Results

A total of 1199 GERD patients and 1428 controls were included in current meta-analysis. The combined results showed there were no association of IL-1B-511 gene polymorphism and GERD susceptibility (allele T vs C OR = 0.98, 95 % CI 0.79–1.23; genotype TT&TC vs CC OR = 0.91, 95 % CI 0.64–1.28).

Conclusion

This meta-analysis suggested that the genetic polymorphism of IL-1B-511 might not be associated with susceptibility of GERD.
Literature
1.
Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2013;108(3):308–28 quiz 329.PubMedCrossRef
2.
French-Belgian Consensus Conference on Adult Gastro-oesophageal Reflux Disease ‘Diagnosis and Treatment’: report of a meeting held in Paris, France, on 21–22 January 1999. The Jury of the consensus conference. Eur J Gastroenterol Hepatol. 2000;12(1):129–37.
3.
Armstrong D, Marshall JK, Chiba N, Enns R, Fallone CA, Fass R, et al. Canadian Consensus Conference on the management of gastroesophageal reflux disease in adults—update 2004. Can J Gastroenterol. 2005;19((1):15–35.PubMed
4.
Katelaris P, Holloway R, Talley N, Gotley D, WilliamsJ S. Dent, Gastro-oesophageal reflux disease in adults: Guidelines for clinicians. J Gastroenterol Hepatol. 2002;17(8):825–33.PubMedCrossRef
5.
Koop H, Schepp W, Muller-Lissner S, Madisch A, Micklefield G, Messmann H, et al. Consensus conference of the DGVS on gastroesophageal reflux. Z Gastroenterol. 2005;43(2):163–4.PubMedCrossRef
6.
Moraes-Filho J, Cecconello I, Gama-Rodrigues J, Castro L, Henry MA, Meneghelli UG, et al. Brazilian consensus on gastroesophageal reflux disease: proposals for assessment, classification, and management. Am J Gastroenterol. 2002;97(2):241–8.PubMedCrossRef
7.
Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006;101(8):1900–20 quiz 1943.PubMedCrossRef
8.
Fock KM, Talley N, Hunt R, Fass R, Nandurkar S, Lam SK, et al. Report of the Asia-Pacific consensus on the management of gastroesophageal reflux disease. J Gastroenterol Hepatol. 2004;19(4):357–67.PubMedCrossRef
9.
Ghoshal UCD. Chourasia, gastroesophageal reflux disease and helicobacter pylori: what may be the relationship? J Neurogastroenterol Motil. 2010;16(3):243–50.PubMedPubMedCentralCrossRef
10.
Holtmann G, AdamT B. Liebregts, Review article: the patient with gastro-oesophageal reflux disease—lifestyle advice and medication. Aliment Pharmacol Ther. 2004;20(Suppl 8):24–7.PubMedCrossRef
11.
Cameron AJ, Lagergren J, Henriksson C, Nyren O, Locke GR 3rd, Pedersen NL. Gastroesophageal reflux disease in monozygotic and dizygotic twins. Gastroenterology. 2002;122(1):55–9.PubMedCrossRef
12.
13.
Dinarello CA. Biologic basis for interleukin-1 in disease. Blood. 1996;87(6):2095–147.PubMed
14.
15.
El-Omar EM, Carrington M, Chow WH, McColl KE, Bream JH, Young HA, et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature. 2000;404(6776):398–402.PubMedCrossRef
16.
Kanemoto K, Kawasaki J, Miyamoto T, ObayashiM H. Nishimura, Interleukin (IL)1beta, IL-1alpha, and IL-1 receptor antagonist gene polymorphisms in patients with temporal lobe epilepsy. Ann Neurol. 2000;47(5):571–4.PubMedCrossRef
17.
Hwang IR, Kodama T, Kikuchi S, Sakai K, Peterson LE, Graham DY, et al. Effect of interleukin 1 polymorphisms on gastric mucosal interleukin 1beta production in Helicobacter pylori infection. Gastroenterology. 2002;123(6):1793–803.PubMedCrossRef
18.
Kauffman MA, Moron DG, Consalvo D, BelloS R. Kochen, Association study between interleukin 1 beta gene and epileptic disorders: a HuGe review and meta-analysis. Genet Med. 2008;10(2):83–8.PubMedCrossRef
19.
Sugimoto M, FurutaY T. Yamaoka, Influence of inflammatory cytokine polymorphisms on eradication rates of Helicobacter pylori. J Gastroenterol Hepatol. 2009;24(11):1725–32.PubMedPubMedCentralCrossRef
20.
Chourasia D, Achyut BR, Tripathi S, Mittal B, Mittal RD, Ghoshal UC. Genotypic and functional roles of IL-1B and IL-1RN on the risk of gastroesophageal reflux disease: the presence of IL-1B-511*T/IL-1RN*1 (T1) haplotype may protect against the disease. Am J Gastroenterol. 2009;104(11):2704–13.PubMedCrossRef
21.
Kim JJ, Kim N, Hwang S, Kim JY, Choi YJ, Lee DH, et al. Relationship of interleukin-1beta levels and gastroesophageal reflux disease in Korea. J Gastroenterol Hepatol. 2013;28(1):90–8.PubMedCrossRef
22.
Cheng HH, Chang CS, Wang HJ, Wang WC. Interleukin-1beta and -10 polymorphisms influence erosive reflux esophagitis and gastritis in Taiwanese patients. J Gastroenterol Hepatol. 2010;25(8):1443–51.PubMedCrossRef
23.
Izakovicova Holla L, Borilova Linhartova P, Hrdlickova B, Marek F, Dolina J, Rihak V, et al. Haplotypes of the IL-1 gene cluster are associated with gastroesophageal reflux disease and Barrett’s esophagus. Hum Immunol. 2013;74((9):1161–9.PubMedCrossRef
24.
Muramatsu A, Azuma T, Okuda T, Satomi S, Ohtani M, Lee S, et al. Association between interleukin-1beta-511C/T polymorphism and reflux esophagitis in Japan. J Gastroenterol. 2005;40(9):873–7.PubMedCrossRef
25.
Queiroz DM, Guerra JB, Rocha GA, Rocha AM, Santos A, De Oliveira AG, et al. IL1B and IL1RN polymorphic genes and Helicobacter pylori cagA strains decrease the risk of reflux esophagitis. Gastroenterology. 2004;127(1):73–9.PubMedCrossRef
26.
Cheng P, Yalei W, Jianming X. Relationship between gene polymorphisms of IL-1β or IL-1RN and gastroesophageal reflux disease. Acta Universitatis Medicinalis Anhui. 2012;47(4):442–5.
27.
Zhang Y, Li Z. Gastroesophageal reflux disease interleulcins-β1, interleukins-1 receptor antagonist gene polymorphism research. Chin J Diffic Compl Cas. 2013;12(3):194–6.
28.
Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700.PubMedPubMedCentralCrossRef
29.
DeVault KRDO. Castell, Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol. 2005;100(1):190–200.PubMedCrossRef
30.
Chong VH, Padam BC, HermantaJ RG. Anand, Gastro-oesophageal reflux disorders among Nepalese residing in Southeast Asia. Med J Malaysia. 2013;68(3):234–8.PubMed
31.
Kandulski AP. Malfertheiner, Gastroesophageal reflux disease–from reflux episodes to mucosal inflammation. Nat Rev Gastroenterol Hepatol. 2012;9(1):15–22.CrossRef
32.
Mansour-Ghanaei F, Joukar F, Atshani SM, ChagharvandF S. Souti, The epidemiology of gastroesophageal reflux disease: a survey on the prevalence and the associated factors in a random sample of the general population in the Northern part of Iran. Int J Mol Epidemiol Genet. 2013;4(3):175–82.PubMedPubMedCentral
33.
Ek WE, Levine DM, D’Amato M, Pedersen NL, Magnusson PK, Bresso F, et al. Germline genetic contributions to risk for esophageal adenocarcinoma, Barrett’s esophagus, and gastroesophageal reflux. J Natl Cancer Inst. 2013;105(22):1711–8.PubMedPubMedCentralCrossRef
34.
Steinkasserer A, Spurr NK, Cox S. P. JeggoR.B. Sim, The human IL-1 receptor antagonist gene (IL1RN) maps to chromosome 2q14-q21, in the region of the IL-1 alpha and IL-1 beta loci. Genomics. 1992;13(3):654–7.PubMedCrossRef
35.
Metadata
Title
Association of interleukin-1B gene polymorphisms at site 511 with gastroesophageal reflux disease: a meta-analysis
Authors
Minmin Xue
Sujuan Zhang
Jia Li
Wei Li
Dongxu Wang
Publication date
01-01-2016
Publisher
Springer Japan
Published in
Esophagus / Issue 1/2016
Print ISSN: 1612-9059
Electronic ISSN: 1612-9067
DOI
https://doi.org/10.1007/s10388-015-0498-0

Other articles of this Issue 1/2016

Esophagus 1/2016 Go to the issue

Original Article

Role of fibroblast growth factor receptors in esophageal squamous cell carcinoma

Original Article

Differences in the endoscopic detection rates of Barrett’s esophagus using the Japanese and Western criteria: a pilot study

Original Article

Gastric tube cancer after radical esophagectomy: comparison of two periods in a single center

Original Article

Endoscopic steroid injection reduced frequency of repeat dilation in patients with anastomotic stenosis after esophagectomy

Original Article

Combination of continuous paravertebral block and epidural anesthesia in postoperative pain control after esophagectomy

Original Article

Characteristics and diagnosis of esophageal basaloid squamous cell carcinoma
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits